Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Immunology Immunology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christoph Hoeller is an Associate Professor and Head of the Skin Cancer Center at the Medical University of Vienna, Austria. His research focuses on melanoma treatment, including adjuvant immunotherapy and the management of skin reactions from topical treatments. He has contributed to various recent articles that explore immunotherapy outcomes and the effects of DNA methylation on treatment response in metastatic melanoma.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (7)

vanna chiarion sileni

Chief of Melanoma Oncology Unit

ITALY

View details

Julia Maria Ressler

Medical University of Vienna

AUSTRIA

View details

Verena Paulitschke

Medical University of Vienna

AUSTRIA

View details

Tarek Meniawy

University of Western Australia

AUSTRALIA

View details

Peter Petzelbauer

Medical University of Vienna

AUSTRIA

View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES

View details

Micaela Hernberg

Associate professor

University of Helsinki

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christoph Hoeller

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment<i> -</i> Update 2024

Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Plain language summary of the CheckMate 76K study results

BRAF Inhibition and UVB Light Synergistically Promote <i>Mus musculus</i> Papillomavirus 1-Induced Skin Tumorigenesis

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

Collaborators (7)

vanna chiarion sileni

Julia Maria Ressler

Verena Paulitschke

Tarek Meniawy

Peter Petzelbauer

John Kirkwood

Micaela Hernberg

Make your next move.